Gilead to buy 49.9% stake in cancer drug developer Pionyr for $275 million

This post was originally published on this site
https://i-invdn-com.akamaized.net/trkd-images/LYNXMPEG5M15S_L.jpg

The drugmaker said it has also secured the right to acquire remainder of Pionyr for a $315 million option exercise fee.

Add Comment